Skip to main content
. Author manuscript; available in PMC: 2009 Jan 1.
Published in final edited form as: Gastroenterology. 2007 Oct 17;134(1):120–130. doi: 10.1053/j.gastro.2007.10.023

Figure 2. MAPK/ERK signaling mediates the pro-proliferative effect of oncogenic KRAS.

Figure 2

(A) IEC-iKRAS cells were treated with or without 5 mM IPTG for 48 h. Fifty μM PD98059 or DMSO (vehicle control) were added 24 h following the addition of IPTG. Western blot analyses were performed using KLF5, phospho-ERK (p-ERK) and ERK antibodies. (B) Cell proliferation was measured under the treatment conditions depicted in the panel. N = 6; * p < 0.05 when compared to DMSO-treated cells.